Cyclodextrins at CPHI

news, Today's cyclodextrin, ,

he world’s largest pharmaceutical exhibition, CPHI Worldwide 2025, took place in Frankfurt between 28–30 October, bringing together the global pharma community under one roof.

With more than 60,000 attendees, 2,400 exhibitors, and representatives from over 160 countries, the event once again showcased innovation across every sector — from ingredients and FDF to packaging, outsourcing, and biopharmaceuticals.

Cyclodextrins were once again in the spotlight. Key players exhibiting such as WACKER, Roquette, CarboHyde, and Zibo Qianhui Biological Technology Co., Ltd., Shandong Binzhou Zhiyuan Biotechnology Co., Xi’an DELI Biochemical Industry Co, together with distributors like Ashland and Barentz, represented the backbone of the CD industry.

Numerous pharma companies also highlighted cyclodextrin-enabled formulations, including Sugammadex API producers and integrated CD-based drug delivery innovators.

Carbo CPHI CarboHyde

CarboHyde was proud to be part of it all — represented by Daniel Bisericaru, Balázs Kondoros, Tamás Vargadi, and Tamás Sohajda — meeting partners, exploring new ideas, and strengthening collaborations around next-generation cyclodextrin projects.

We have seen – beyond the traditional applications – interest in nutraceutical, wound healing, mucoadhesive, vaccine, protein, targeted drug delivery and many applications.

Thank you to everyone we met in Frankfurt — your passion and insights continue to drive the evolution of CD science and its pharmaceutical applications.

See you next year in Milan!

Highlights from the Largest Pharma Event of the Year in Milan

news

Last week, the largest pharmaceutical exhibition of the year took place in Milan. CPHI, recognized as the world’s premier pharmaceutical event, hosts six distinct exhibitions covering the entire pharmaceutical sector—from ingredients and finished dosage forms (FDF) to machinery, packaging, outsourcing, and biopharmaceuticals.

Over 2,300 exhibitors presented their products and services to approximately 60,000 attendees, representing every part of the pharmaceutical supply chain, all within three days. CPHI provides a unique opportunity for professionals to connect, explore innovations, and stay up-to-date with the latest developments in the industry.

Tamás Sohajda, Gergely Tóth, and Tamas Vargadi represented CarboHyde. Throughout the event, they participated in around 80 meetings with partners, exhibitors, and new connections. Despite the pharmaceutical industry’s ever-changing landscape, CPHI remains one of the best venues for networking, bringing together professionals from across the sector in one place.

The event provided an opportunity to engage with Sugammadex manufacturers, cyclodextrin producers and formulators, contract manufacturing organizations (CMOs), formulation experts, as well as professionals from R&D, procurement, business development, and more.

CPHI offered those interested in cyclodextrins the chance to connect with many key players. Attendees could meet Sugammadex API manufacturers, integrated pharma companies using cyclodextrins in their formulations, and major manufacturers such as WACKER, Roquette, Cyclolab R&D Ltd. or Zibo Qianhui Biological Technology Co.,Ltd. Distributors such as Ashland and Barentz were also present, showcasing their products and services.

I highly recommend CPHI to anyone who has yet to experience it. The 2025 edition promises to be another invaluable event filled with opportunities to learn, connect, and grow within the industry.

In the coming weeks, CarboHyde will continue to focus on using cyclodextrins as active ingredients, with content covering their application in treating various diseases.

How do you see the future of cell and gene therapy?

drug development, , ,

Our concise outlook is the following:

Transformational Potential: Cell and gene therapies are revolutionizing how we treat diseases, promising to cure certain conditions.
They remain at the forefront of healthcare innovation.

Fast-Growing Field: These therapies are the fastest-growing therapeutics areas, with over 50 new in vivo and ex vivo gene therapy launches planned in the next few years.

Challenges and Innovation: While promising, cell and gene therapies require substantial innovation to unlock their full potential for patients. Scaling digital and analytics in discovery and R&D is part of the solution.

Market Resilience: Despite the disruptions caused by the pandemic, stakeholders, including CGT innovators, healthcare providers, and CDMOs, are optimistic that positive developments lie ahead.

Viral-Vector Therapies: Viral-vector gene therapies are here to stay, but addressing challenges and strategizing for patient access is critical for their success.

Overall, the outlook is positive, but ongoing research, regulatory advancements, and manufacturing innovations will shape the future of cell and gene therapy. 🌟

CarboHyde CEO Tamas Sohajda Presents at CPHI NA on Novel Uses of Cyclodextrins in the Pharmaceutical Industry

news, ,

CarboHyde CEO Tamas Sohajda recently delivered a compelling presentation at the CPHI North America conference, focusing on innovative applications of cyclodextrins in the pharmaceutical industry. His talk highlighted how these unique cyclic oligosaccharides can enhance drug delivery, improve solubility, and stabilize formulations, offering significant benefits to pharmaceutical development.

Cyclodextrins, known for their ability to form inclusion complexes with various molecules, have been extensively studied for their potential to revolutionize drug formulations. Sohajda’s presentation delved into recent advancements and case studies demonstrating the successful integration of cyclodextrins in new drug delivery systems. These developments promise to improve the efficacy and safety of numerous medications, addressing longstanding challenges in drug formulation and bioavailability.

The talk received considerable attention from industry professionals, underscoring CarboHyde’s leading role in pioneering the use of cyclodextrins for pharmaceutical innovation. Attendees had the opportunity to engage with Sohajda, discussing cyclodextrin research’s practical applications and future directions.

A video of the event is available on CPHI website – after a registration – for those who missed the presentation or wish to revisit the insights shared.

CPHI: Lightning Round: Excipients 4.0 – Cyclodextrins (CDs) (video) (cphi-online.com)

On Vimeo:

Dr Tamas Sohajda Lightning Round Excipients 4.0 – Cyclodextrins CDs on Vimeo

Stay tuned for more updates from CarboHyde as they continue to push the boundaries of pharmaceutical technology.

Our CEO, Tamas Sohajda, presented at CPhI North America

news,

Here are a few words from Tamás about the conference:

A few weeks ago at CPHI North America, I had the pleasure of helping the audience peek into the future of cyclodextrins by showcasing some of the applications we are working on at CarboHyde such as:
– therapeutic cyclodextrins and their development
– using cyclodextrins in vaccines
– using cyclodextrins for gene delivery

I had never spoken at CPHI before, yet it was a fascinating experience, mainly due to James Reidy’s fantastic support.

CarboHyde CEO presenting at CPHI North America

news,

We are proud to announce that our CEO, Tamas Sohajda, will deliver a talk at CPHI North America in Philadelphia in May 2024.
You can learn more about the “Exploring Excipients” session and other speakers, Denise Reaves, M.S from Jurata Thin Film, and Björn-Hendrik Peters from Bristol Myers Squibb here: 
https://www.cphi.com/northamerica/en/agenda/programme/Conference-agenda/exploring-excipients.html.

About the talk:
Explore novel applications in neurodegenerative diseases, gene therapy, and biotechnology, showcasing innovative structures, mechanisms, challenges, and results, with a focus on Alzheimer’s, Parkinson’s, rare genetic disorders, and potential expansion to longevity and infectious diseases, presenting a non-viral gene delivery platform and demonstrating CD utilization in vaccine adjuvants and biotechnological tools.